Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease

Phase 4

Recruiting

• Conditions: Chronic Kidney Disease

• Registration Number: NCT03826147
• Lead Sponsor: University of Colorado, Boulder

Brief Summary

Nitric oxide (NO) is an essential molecule in the body that is decreased in patients with chronic kidney disease (CKD), leading to reductions in vascular, movement ("motor") and cognitive functions. This study will determine if daily oral supplementation (3 months) with a supplement that increases NO in the body, i.e., nitrate-rich beetroot juice, improves vascular, motor and cognitive function in patients with CKD; this study will also provide insight into the biological reasons (mechanisms) by which supplementation with nitrate-rich beetroot juice improves vascular function in these patients. Overall, this research will provide scientific evidence supporting the use of nitrate-rich beetroot juice for preserving physiological function and preventing co-morbid clinical conditions and disability in CKD.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-01-28
• Study First Submitted QC: 2019-01-29
• Study First Posted: 2019-02-01
• Study Start: 2019-05-01
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-15
• Last Update Posted: 2023-05-17
• Primary Completion: 2023-07
• Study Completion: 2024-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

• CKD stage II-IV (eGFR using the Modification of Diet in Renal Disease (MDRD) prediction equation 20-90 mL/min/1.73m2; stable renal function in the past 3 months)
• Ability to give informed consent
• Albumin > 3.0 g/dL
• Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk for 6 min, climb 10 stairs)
• Free from alcohol dependence or abuse, as defined by the American Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
• Mini-mental state examination score >21 (rationale: to screen for subjects with major cognitive impairment)
• Blood pressure (BP) >100/60 mmHg for past 3 months (rationale: blood pressure below 100/60 mmHg may elevate the normally small risk of hypotension with nitrate supplementation)
• Not taking medications that will interfere with administered medications (e.g., sildenafil interacts with nitroglycerin)
• Body mass index (BMI) <40 kg/m2 (vascular function measurements can be inaccurate in severely obese patients)

Exclusion Criteria

• Life expectancy <1 year
• Uncontrolled hypertension, defined as blood pressure > 160/100 mmHg in the past 3 months
• History of severe liver disease
• History of severe congestive heart failure (i.e., ejection fraction < 35%)
• History of hospitalizations within the last 3 months
• Active infection or antibiotic therapy
• Warfarin use
• Vasculitis requiring immunosuppressive therapy within the last year
• High dietary nitrate intake or current nitrate/nitrite supplementation; hypersensitivity to nitrates or nitrites
• Glucose-6-phosphate dehydrogenase deficiency or blood methemoglobin >2%
• Unwilling to abstain from use of mouthwash or other oral hygiene practices (e.g., tongue scraping) outside of teeth brushing that disrupt the oral microbiome and would interfere with nitrate conversion to nitrite
• Blood donation within 8 weeks prior to enrolling in the study; unwilling to abstain from donating blood for 8 weeks after completing the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in aortic stiffness	Baseline, 3 months	as measured by carotid-femoral pulse wave velocity
Change in vascular endothelial function	Baseline, 3 months	as measured by brachial artery flow-mediated dilation

Secondary Outcome Measures

Name	Time	Method
Change in endothelial cell markers of oxidative stress	Baseline, 3 months	Endothelial cell nitrotyrosine levels will be determined
Change in oxidative stress-associated suppression of endothelial function assessed as the increase in brachial artery flow-mediated dilation following an ascorbic acid infusion	Baseline, 3 months	The influence of oxidative stress on brachial artery flow-mediated dilation will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline

Trial Locations

Locations (1)

Integrative Physiology of Aging Laboratory; 🇺🇸 Boulder, Colorado, United States